Stay informed with key topics, webinars and podcasts
Webinars & Podcasts
Trending Topics
Is your organization prepared for the dramatically rising costs of healthcare?
Public spending on healthcare has risen dramatically in the United States from just under 50% of total healthcare spending in 2013 to 81-82% of total healthcare spending in 2014-2016.
Life sciences
Despite political and social unrest percolating in parts of the region, the Middle East pharmaceutical market is experiencing strong growth. With government policies and investments supporting the growing healthcare infrastructure, multinational companies are seeing keen opportunities to tap into the region’s economic potential.
Gain access to POLI Strat
Today, you face greater challenges than ever before in pricing and receiving reimbursements for your products.
Impact of ESG
Today’s ESG developments mean that the demands on market access and planning professionals will only become more challenging and complex.
7 biggest trends impacting pharma market access and pricing in 2021 and beyond
The global COVID-19 pandemic brought to the forefront the critical importance of healthcare-and the healthcare industry-in ways not seen for generations.
Pharma pricing strategy aduhelm effect
The ongoing controversy over Biogen’s Aduhelm treatment shows that pricing scrutiny has risen to a new level.
International reference pricing 2017
Despite the emergence of risk-sharing agreements and prevalence of discounting, international reference pricing (IRP) remains at the center of pharmaceutical price controls across many countries worldwide.
Complimentary access industry-leading global pharmaceutical pricing data
For firms seeking to analyze the impact of President Trump’s executive order on international reference pricing.
Methodology of the rebate sharing model for the commercially insured
An economic model was constructed to estimate the impact of passing through a share of negotiated manufacturer rebates to patients with commercial insurance at the point of sale (POS).
The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes
Diabetes is one of the most prevalent and expensive medical conditions in the U.S. Today, nearly half of adults in the U.S.
Passing a Portion of Negotiated Rebates Through to Seniors with Diabetes Can Improve Adherence and Generate Savings in Medicare
Diabetes imposes a significant economic burden on Medicare, at a cost of more than $100 billion annually.